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Abstract
Background: Contrary to pancreatic adenocarcinoma, pancreatic neuroendocrine tumours (PNET) are
commonly hyperenhancing on arterial phase computed tomography (APCT). However, a subset of these
tumours can be hypoenhancing. The prognostic significance of the CT appearance of these tumors
remains unclear.
Methods: From 2001 to 2012, 146 patients with well-differentiated PNET underwent surgical resection.
The degree of tumour enhancement on APCT was recorded and correlated with clinicopathological
variables and overall survival.
Results: APCT images were available for re-review in 118 patients (81%). The majority had hyperen-
hancing tumours (n = 80, 68%), 12 (10%) were isoenhancing (including cases where no mass was
visualized) and 26 (22%) were hypoenhancing. Hypoenhancing PNET were larger, more commonly
intermediate grade, and had higher rates of lymph node and synchronous liver metastases. Hypoen-
hancing PNET were also associated with significantly worse overall survival after a resection as opposed
to isoenhancing and hyperenhancing tumours (5-year, 54% versus 89% versus 93%). On multivariate
analysis of factors available pre-operatively, only hypoenhancement (HR 2.32, P = 0.02) was independ-
ently associated with survival.
Discussion: Hypoenhancement on APCT was noted in 22% of well-differentiated PNET and was an
independent predictor of poor outcome. This information can inform pre-operative decisions in the
multidisciplinary treatment of these neoplasms.
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Introduction
Neuroendocrine tumours are a heterogeneous group of epithelial
neoplasms that can originate from almost any organ derived from
the primitive endoderm, including pancreatic islet cells.1 While
pancreatic neuroendocrine tumours (PNET) account for only 2%
of all pancreatic neoplasms, with an annual incidence between 2
to 5 cases per million individuals, their incidence appears to be
rising.2–6 PNET are classically characterized as slow-growing and
indolent tumors; however, aggressive tumours with early invasion
and metastases have also been described. Definitive management
of PNET includes complete removal of the tumour and any meta-
static disease, as surgery remains the only treatment modality that
can result in a cure.7–12 As many of these tumours display an
indolent course, many surgeons opt for enucleation of small,
superficial lesions in order to preserve pancreatic parenchyma and
reduce the risk of pancreatic insufficiency.13–16 Larger tumours or
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those with pre-operative evidence of locoregional spread or
distant metastases generally require formal pancreatic resection;
indeed, when feasible, aggressive resection including vascular
reconstruction and liver metastasectomy may allow for excellent
long-term prognosis given the generally slow progression of these
tumours.17–21
Numerous post-operative variables have been identified to
predict prognosis after resection of PNET, including histological
grade, Ki-67 proliferative index, mitotic count, evidence of necro-
sis, perineural or lymphovascular invasion and lymph node
metastasis.22–29 Identification of pre-operative prognostic variables
remains somewhat vague yet important, as these could potentially
guide treatment strategy. Although discrepancies exist, older age,
tumour size, the presence of distant metastases and a lack of
hormone hypersecretion (likely owing to late presentation) have
previously been shown to be independent pre-operative predic-
tors of a worse prognosis.27–33
In an attempt to improve pre-operative prognostic stratifica-
tion, recent studies have evaluated imaging characteristics of
PNET that may suggest a more aggressive behaviour.34–37 Our
group recently showed that the presence of calcifications on
pre-operative computed tomography correlated with inter-
mediate grade and metastases in well-differentiated PNET.34
Typically, PNET display a characteristic hyperenhancing pattern
on the arterial phase of computed tomography (APCT), owing
to the hypervascular nature of these tumours. A consistent
number of PNET, however, appear hypoenhancing or heteroge-
neous on APCT.38–41 A previous pilot study by Rodallec et al37 has
demonstrated a correlation between hypoenhancing tumours
and poor differentiation as well as decreased survival; however,
almost half (18 of 37) of the patients included in this study
did not undergo surgery, making survival comparisons and
definitive confirmation of the tumour’s pathological character-
istics problematic. In addition, this study only analysed the area
of highest enhancement and did not account for tumour
heterogeneity.
The goal of this study was to more accurately examine the
enhancement patterns of well-differentiated PNET on pre-
operative CT. Specifically we hoped to delineate the prevalence
of hypoenhancement on APCT in these tumours and correlate
this finding with histopathological features and survival after
resection.
Patients and methods
A retrospective cohort study was conducted on all patients who
underwent a surgical resection of a PNET at Stanford University
Medical Center between 2001 and 2012, and for whom pre-
operative APCT images were available for re-review. Patients
with synchronous liver metastases who underwent a combined
or staged liver resection or ablation were included in the study.
Patients with high-grade PNET (G3), defined as having a mitotic
rate of >20 per 10 High Power Fields (HPF), and/or a Ki-67of
>20%, are typically managed with systemic chemotherapy at
our institution and were excluded from the study.1 The study
was approved by the Stanford University institutional review
board.
The operative techniques have been described previously.19,20,42
Small, superficial tumours were enucleated provided the integrity
of the pancreatic duct could be maintained. Additionally, unless
the tumour enucleated was an insulinoma, a detailed removal
of peripancreatic lymph nodes was performed.43,44 Specifically,
for head/neck tumors, after a wide Kocher manoeuver, the lym-
phatic tissue posterior to the head of the pancreas and in the
portocaval/hepatic artery space was removed. For body/tail
tumours, peri-pancreatic lymph node sampling was accom-
plished with a deliberate dissection to remove nodes around the
hepatic and splenic arteries. Larger tumours that could not be
enucleated were resected with a pancreaticoduodenectomy,
central pancreatectomy or distal pancreatectomy. The latter was
done via open or laparoscopic approach, per the discretion of the
surgeon. If liver metastases were present, they were addressed
primarily with anatomic or non-anatomic liver resection, or
alternatively with thermal ablation or a combination of resection
and ablation.17
Demographic, clinical and pathological data were retrospec-
tively reviewed. Age, gender, operative details and tumour charac-
teristics (location, size, multifocality, differentiation, mitotic rate,
Ki-67 immunostaining, necrosis, perineural or lymphovascular
invasion and lymph node or liver metastases) were recorded.
Intermediate grade tumours (G2) were defined by the presence of
at least one of the following criteria: mitotic rate of 2–20 per 10
HPF, Ki-67 labelling index of 3–20%, the presence of necrosis and
perineural or lymphovascular invasion.1,45 In the absence of any of
the aforementioned criteria, the tumour was considered low grade
(G1, mitotic rate <2/10 HPF, Ki-67 <3%). Functionality was based
on the presence of the relevant clinical syndromes combined with
biochemical evidence of hormonal excess. Vital status at last
follow-up was obtained through a combined review of the
medical record, Social Security Index and the California Cancer
Registry.
All APCT images were re-reviewed using Centricity PACS
(picture archiving and communication system; General Electric,
Fairfield, CT, USA). Images were reviewed simultaneously by the
first (D.J.W.) and last (G.A.P.) authors after a consensus was
defined by these authors and the radiologist involved (P.D.P.) as to
how the lesions should be categorized. The degree of tumour
arterial enhancement was determined by comparison with the
surrounding pancreatic parenchyma. Care was taken to avoid
areas of calcifications, peritumoral areas of pancreatitis or adja-
cent normal vasculature when assessing tumour enhancement.
When multiple tumours were present in one patient, the charac-
teristics of the largest tumour were recorded. Non-contrast-phase
CT images were also reviewed to record the presence of calcifica-
tions within the primary tumour. Finally, uptake on octreoscan
was correlated with the enhancement pattern on APCT.
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Statistical analysis
Categorical variables were presented as counts (percentages) and
compared using Fisher’s exact and chi-square tests. Continuous
variables were presented as mean [standard deviation (SD)] and
compared by one-way analysis of variance (anova) tests. Survival
probabilities were calculated by the Kaplan–Meier method and
compared using the log rank test. Multivariate analysis of pre-
operative factors predictive of survival was performed by Cox
regression analysis. The level of statistical significance was set to
P < 0.05.
Results
From 2001 to 2012, 146 patients with well-differentiated PNET
underwent surgical resection at our institution. Pre-operative
APCT images were available for 118 patients (81%), and this
group constituted our study cohort. The clinicopathological char-
acteristics of the cohort are shown in Table 1. Synchronous liver
metastases were present in 30 patients (25%) and were addressed
with combined or staged liver resection or thermal ablation with
potentially curative intent. Additional work-up to include biopsy
or fine-needle aspiration was performed in 66 patients (56%) and
rendered a diagnosis of neuroendocrine tumour in 58 patients
(49%).
Review of pre-operative APCT images identified five dominant
patterns for PNET enhancement (Fig. 1). Eighty (68%) tumours
were hyperenhancing, of which 75 (64%) were solid appearing
Table 1 Clinicopathological characteristics of 118 patients with pan-
creatic neuroendocrine tumours
Characteristic
Age, mean (SD) 55 (14)
Male gender (%) 62 (53)
Pre-operative tissue diagnosis 58 (49)
Mean size of tumour, cm (SD) 3.68 (3.3)
Multifocal tumours (%) 11 (9)
Enucleation (%) 14 (12)
Vascular resection/reconstruction (%) 11 (9)
Location
Head/Uncinate (%) 41 (34)
Body/Tail (%) 74 (62)
Diffuse (%) 4 (3)
Calcifications present (%) 22 (19)
Functional (%) 30 (25)
Insulinoma (%) 21 (18)
Gastrinoma (%) 4 (3)
Glucagonoma (%) 3 (3)
VIPoma (%) 1 (1)
MEN I (%) 11 (9)
Positive Margin 35 (30)
Grade
Low grade (%) 67 (57)
Intermediate grade (%) 51 (43)
Lymph node metastasis (%)* 33 (33)
Synchronous liver metastasis (%) 30 (25)
* 99 patients had at least 1 lymph node evaluated pathologically
(a)
(b)
(c)
(d)
(e)
Figure 1 Representative images of the 5 types of enhancement
pattern on arterial phase computed tomography. Two images are
shown for each type. Hyperenhancing, solid (a); Cystic with hyper-
enhancing rim (b); Isoenhancing or no mass visualized (c); Homo-
geneously hypoenhancing (d); Heterogeneous but mostly
hypoenhancing with some peripheral enhancement (e)
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and 5 (4%) were cystic with rim enhancement. Two (2%) tumours
were isoenhancing whereas 10 (8%) tumours were not visualized
on pre-operative CT. A total of 26 (22%) tumours were hypoen-
hancing, of which 12 (10%) were homogeneously hypoenhancing
and 14 (12%) were heterogeneous but mostly hypoenhancing,
with some degree of peripheral enhancement (Fig. 2). Of the 38
patients in our cohort who had isoenhancing or hypoenhancing
tumours, 28 patients underwent a pre-operative biopsy. Seventeen
were endoscopic ultrasound-guided and 11 were percutaneous
(mostly of liver metastases). Twenty-five of these yielded a diag-
nosis of neuroendocrine tumour. Of the 10 patients with no mass
visualized, 3 had pre-operative tissue diagnosis via endoscopic
ultrasound/fine-needle aspiration, 3 had tumours detectable by
EUS without definitive pathological diagnosis, 1 had a pre-
operative diagnosis based on percutaneous biopsy of a liver mass,
1 had clinical and biochemical evidence of Zollinger–Ellison syn-
drome and positive octreoscan, 1 had clinical and biochemical
diagnosis of insulinoma and a calcium angiogram localizing the
lesion and 1 had an ERCP showing a biliary stricture.
In our cohort, 11 patients were found to have multifocal
tumours on final pathology. Five (45%) had multifocal tumours
on pre-operative imaging. The enhancement pattern in these five
patients was uniform across all tumours. Additionally, 30 patients
(25%) were found to have synchronous liver metastases. Interest-
ingly, the enhancement pattern of the liver metastases matched
the pattern of the primary pancreatic tumour in only 60% of
these patients. The consistency between pancreatic tumour and
liver metastasis enhancement was highest for the hyperenhancing
pancreatic tumours (86%). Twelve of the 14 patients with hyper-
enhancing pancreatic tumours had hyperenhancing liver metas-
tases, whereas 1 patient had hypoenhancing liver metastases and
the remaining patient did not have metastases noted on pre-
operative imaging. The 2 patients with isoenhancing pancreatic
tumours had hyperenhancing liver metastases. Of the 14 patients
with hypoenhancing pancreatic tumours, only 6 had hypoen-
hancing liver metastases and the remaining 8 had hyperenhanc-
ing liver metastases. A pre-operative octreoscan was performed in
32 patients (27%), with 20 of these (63%) having a positive scan
(identifying the pancreatic tumor). Uptake on octreoscan did not
correlate with degree of enhancement on APCT. Octreoscan was
positive in 62% of patients with hyperenhancing tumours (13 out
of 21), 60% of patients with isoenhancing tumours (3 out of
5) and 67% of patients with hypoenhancing tumours (4 out of 6).
A comparison of clinicopathological characteristics among the
five patterns of enhancement is shown in Table 2. Age, gender,
multifocality, location in the pancreas, presence of calcifications,
tumour functionality and margin status were similar among the
groups. Additionally, the rates of enucleation (versus formal resec-
tion) and vascular resection or reconstruction were similar among
the groups. However, both groups of hypoenhancing PNET were
larger (P < 0.001), more likely to have necrosis on pathological
evaluation, more likely to be intermediate grade (P < 0.001) and
associated with lymph node (P < 0.001) or synchronous liver
metastases (P = 0.01). Simplifying our enhancement classification
scheme further into three categories (hyperenhancing, isoenhanc-
ing and hypoenhancing) produced the same result, with larger
size, necrosis, intermediate grade, lymph node involvement and
synchronous liver metastases all more prevalent in patients with a
hypoenhancing tumour on preoperative imaging. In addition,
there was a trend for hypoenhancing tumours to be more fre-
quently calcified (P = 0.07).
Because hypoenhancing PNET appeared to display a more
aggressive phenotype, we explored whether survival differences
existed among the three enhancement patterns. After a mean
follow-up of 31 months for the entire cohort, hypoenhancing
PNET were associated with a significantly worse overall survival
Figure 2 Distribution of enhancement pattern on arterial phase computed tomography for 118 patients with pancreatic neuroendocrine tumor
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after a resection, as opposed to isoenhancing and hyperenhancing
tumours (5-year survival, 93% versus 89% versus 54% for hyper-
enhancing, isoenhancing and hypoenhancing tumours, respec-
tively) (Fig. 3).
As hypoenhancing tumours were more commonly larger and
associated with synchronous liver metastases, we sought to
examine whether the association between hypoenhancement and
worse survival held true in multivariate analysis. After controlling
for other variables that are available pre-operatively, such as
tumour size, the presence of synchronous liver metastasis and
functionality, only hypoenhancement on APCT (versus iso- and
hyperenhancement) was independently associated with worse
survival (P = 0.026, Table 3).
Discussion
This study examined the enhancement patterns of well-
differentiated PNET on APCT and its prognostic significance.
While the majority of these tumours are hyperenhancing on
APCT, a subset of them is hypoenhancing (22% in our study).
Hypoenhancing PNET are more likely to have an aggressive phe-
notype, more commonly associated with intermediate grade and
lymph node or synchronous liver metastases. Additionally,
hypoenhancement was associated with an approximate two-fold
reduction in survival after a curative resection, a reduction that
held true even when controlling for other preoperative variables,
such as size, the presence of liver metastases and functionality.
Interestingly, the rates of necrosis were highest in the hypoen-
hancing tumours, although this analysis is somewhat limited as
the minority of pathology reports commented on the presence or
absence of necrosis (41%). Additionally, it is difficult to conclude
that the pattern of enhancement is a function of necrosis (or
percentage of necrosis), as one would expect a higher (or even
100%) rate of necrosis among the hypoenhancing tumours if this
were the case. Alternatively, the presence of necrosis has been
shown to be associated with more aggressive (and higher grade)
Table 2 Clinicopathological features of pancreatic neuroendocrine tumours based on their degree of enhancement on arterial phase
computed tomography
Hyperenhancing
(n = 80)
Isoenhancing
(n = 12)
Hypoenhancing
(n = 26)
P*
Hyper-
enhancing
Solid
(n = 75)
Cystic with
Hyper-enhancing
Rim
(n = 5)
Iso-enhancing
(n = 2) or
No Mass
Visualized
(n = 10)
Homogeneously
Hypo-enhancing
(n = 12)
Heterogeneous
but Mostly
Hypo-enhancing
(n = 14)
P**
Mean Age, years (SD) 56 (14) 54 (10) 52 (14) 53 (15) 54 (12) 0.94 0.48
Male gender 40 (53%) 3 (60%) 6 (50%) 6 (50%) 7 (50%) 1.00 0.95
Pre-operative tissue
diagnosis
32 (43%) 1 (20%) 5 (42%) 9 (75%) 11 (79%) 0.01 0.002
Mean size, cm
(SD)
3.1 (2.6) 2.1 (0.8) 1.7 (1.3) 4.4 (3.2) 8.6 (4.3) <0.001 <0.001
Enucleation 10 (13%) 2 (40%) 1 (8%) 1 (8%) 0 (0%) 0.20 0.36
Vascular resection 6 (8%) 0 (0%) 0 (0%) 3 (25%) 2 (14%) 0.21 0.17
Multifocal tumours 9 (12%) 1 (20%) 1 (8%) 0 (0%) 0 (0%) 0.39 0.15
Head/uncinate location
(versus body/tail)
24 (33%) 3 (60%) 7 (58%) 3 (25%) 4 (29%) 0.30 0.17
Calcifications 13 (17%) 1 (20%) 0 (0%) 4 (33%) 4 (29%) 0.18 0.07
Functional 23 (31%) 1 (20%) 2 (17%) 3 (25%) 1 (7%) 0.41 0.29
Positive margin 23 (31%) 0 (0%) 4 (33%) 6 (50%) 2 (14%) 0.46 0.92
Necrosisa 5 (19%) 0 (0%) 0 (0%) 4 (50%) 5 (63%) 0.02 0.02
Intermediate gradeb 27 (36%) 0 (0%) 4 (33%) 8 (67%) 12 (86%) <0.001 <0.001
Lymph node metastasisc 15 (24%) 0 (0%) 1 (10%) 7 (70%) 10 (71%) <0.001 <0.001
Synchronous liver
metastasis
13 (17%) 1 (20%) 2 (17%) 6 (50%) 8 (57%) 0.01 <0.001
*P-value across three patterns of enhancement (hyperenhancing, isoenhancing and hypoenhancing).
**P-value across five patterns of enhancement.
aPercentage reflects only patients for whom necrosis was commented upon in the pathology report (n = 48).
bIntermediate grade was defined by the presence of at least one of the following: mitotic rate of 2–20/10 HPF, Ki-67 of 3–20%, necrosis, perineural
or lymphovascular invasion on pathologic evaluation.
c99 of 118 patients had at least one lymph node evaluated pathologically.
SD, standard deviation.
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tumours; therefore, hypoenhancing tumours may have higher
rates of necrosis simply as a function of their being more aggres-
sive tumours.
Our findings are in keeping with the findings of a previous
smaller study of 37 patients reported by Rodallec et al.37 In this
study (which included seven patients with high-grade PNET)
hypoenhancing tumours were more likely to be associated with
poor differentiation and worse overall survival. However, prob-
ably because of the small sample size, these findings did not hold
true in multivariate analysis. In a subsequent prospective study
from the same institution, d’Assignies et al. utilized perfusion CT
on 28 patients with PNET and found lower intratumoural blood
flow to be associated with lower microvascular density (the stand-
ard technique used to quantify angiogenesis in histologic studies
by counting vessels on tissue specimens using CD34 immunos-
taining), as well as higher grade tumours, by WHO criteria and the
Ki-67 proliferation index.36 Along the same lines, studies have
suggested that as PNET progress, they lose their angiogenic poten-
tial and their microvascular density decreases.46 This phenom-
enon is in contrast to what is seen in pancreatic adenocarcinoma,
where high microvascular density is associated with decreased
survival.47 This differential relationship between microvascular
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Figure 3 Overall survival after resection of pancreatic neuroendocrine tumors, stratified by their degree of enhancement on arterial phase
computed tomography
Table 3 Multivariate analysis of pre-operative characteristics asso-
ciated with mortality
Characteristic Hazard ratio (95% CI) P-value
Size 0.99 (0.84–1.17) 0.906
Functional 1.01 (0.47–2.39) 0.879
Synchronous liver metastasis 0.64 (0.15–2.67) 0.538
Hypoenhancement on APCT 2.32 (1.11–4.86) 0.026
APCT, arterial phase computed tomography.
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density and outcomes underlines the biological differences
between PNET and pancreatic adenocarcinoma and warrants
further investigation.
Our study has several potential limitations. First, all patients
included in the present study underwent surgery, so there is con-
siderable selection bias towards operative treatment and poten-
tially less advanced disease. However, we elected to include only
patients who underwent surgery so that complete pathological
information is available and survival analysis is meaningful.
Second, evaluating the level of enhancement on APCT was not
quantitative. This was done for several reasons. Many PNET are
heterogeneous or cystic and therefore quantifying the degree of
enhancement using Hounsfield units would be limited by differ-
ences within a single tumour. Also, it was our hope that we could
provide a simplified system for categorizing tumours as enhanc-
ing, isoenhancing or hypoenhancing that relied on the overall
appearance of the tumour. This eventually led to classifying cystic
tumours with rim enhancement as ‘hyperenhancing’ and hetero-
geneous tumours with large areas of hypoenhancement as
‘hypoenhancing’ (even if portions of the latter were hyperenhanc-
ing) based on the biological behaviour of these groups. For the
former, this is actually consistent with the reported literature on
cystic PNET, as these tumours have been reported to have lower
rates of tumour necrosis, perineural and vascular invasion, lymph
node metastasis and synchronous distant metastasis; all findings
consistent with our own study.48 Ultimately, we found that nearly
all the tumours we examined were easily categorized using this
system making it more readily applicable to everyday clinical use.
Third, we concede that variations in the timing of contrast will
play a major role in the enhancement pattern on CT. Although the
vast majority of our study cohort (107 or 91%) had their pre-
operative CT at our institution, where it is our practice to perform
a dedicated pancreatic protocol CT, there can still be minor dif-
ferences in contrast timing that can affect radiological interpreta-
tion of the images.
In conclusion, our study shows that hypoenhancement on arte-
rial phase CT is present in 22% of well-differentiated PNET and is
associated with a more aggressive tumour biology. Hypoenhance-
ment was a more powerful predictor of decreased survival than
established predictors for PNET such as size and presence of
synchronous liver metastases. This information is available pre-
operatively and may inform decision-making in the multidiscipli-
nary treatment of these neoplasms. Patients with hypoenhancing
tumours (even small in size) may benefit from a formal pan-
createctomy with extended lymph node dissection rather than
enucleation. Furthermore, as newer targeted agents inhibiting
angiogenesis, such as everolimus and sunitinib,49,50 are increas-
ingly being used for advanced PNET, the vascularity of these
tumours based on imaging could be prospectively studied as a
predictor of a response to these systemic agents.
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